Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone Intermediate

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez et al. · Journal of Clinical Oncology · 2008 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

Scott Grimm, Heidi J. Einolf, Steven D. Hall et al. · Drug Metabolism and Disposition · 2009 · 306 citations

Medicine, Pharmacokinetics, Pharmacology +17

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

Woon Chien Teng, Jing Wen Oh, Lee Sun New et al. · Molecular Pharmacology · 2010 · 119 citations

Medicine, Oncology, Pharmacology +17

Diethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A)—In vivo and in vitro effects of metabolism by rat liver microsomes—Formation of an oxygenated complex

John B. Schenkman, Beverley J. Wilson, Dominick L. Cinti · Biochemical Pharmacology · 1972 · 119 citations

Medicine, Biochemistry, Pharmacology +13

Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

Stephen Castellino, Michael O'Mara, Kevin M. Koch et al. · Drug Metabolism and Disposition · 2011 · 103 citations

Medicine, Oncology, Pharmacology +17